Dermatol. praxi. 2018;12(3):128-132 [Onkologie. 2018:12(3):111-116]

Primary cutaneous lymphomas in dermatological practice

MUDr. Jiří Ettler$1, MUDr. Jindřich Polívka2, prof. MUDr. Petr Arenberger, DrSc., MBA1
1 Dermatovenerologická klinika 3. LF UK v Praze a Fakultní nemocnice Královské Vinohrady, Praha
2 1. interní klinika – hematologie 1. LF UK v Praze a Všeobecná fakultní nemocnice, Praha

Primary cutaneous lymphomas are a rare type of extranodal non - Hodgkin lymphomas where malignant T-cells or B-cells infiltratethe skin. Most patients with primary cutaneous lymphomas are diagnosed in the early stage of the disease with usually indolentclinical course. However, cases with aggresive behaviour and unfavourable prognosis are not rare. This review summarizes diagnosisand treatment of the most important subtypes of cutaneous lymphomas with emphasis on dermatological manifestationsand skin directed therapy.

Keywords: primary cutaneous lymphomas, mycosis fungoides, skin directed therapy, bexarotene

Published: October 10, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Polívka JEJ, Arenberger P. Primary cutaneous lymphomas in dermatological practice. Dermatol. praxi. 2018;12(3):128-132.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ettler J, Mužík J, Polívka J. Epidemiologie primárních kožních lymfomů v České republice podle dat Národního onkologického registru z let 2005-2015. Onkologie. 2018; 12(3): 100-104. Go to original source...
    2. Polívka J. Primární kožní lymfomy: Současný pohled na vzácná hemato-onkologická onemocnění. Onkologie 2016: 10(2): 66-71. Go to original source...
    3. Polívka J, Ettler J. Role hematologa v multidisciplinární péči o nemocné s kožním lymfomem. Onkologie. 2018; 12(3): 117-122. Go to original source...
    4. Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 2016; 91(1): 151-165. Go to original source... Go to PubMed...
    5. Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. Eur J Cancer. 2017; 77: 57-74. Go to original source...
    6. Kamarádová K. Úskalí diagnostiky kožních lymfomů z pohledu patologa. Onkologie. 2018; 12(3): 105-110. Go to original source...
    7. Frey T. Kožní biopsie. Referátový výběr z dermatovenerologie, 2006; 3: 55-59.
    8. Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol. 2005; 53(6): 1053-1063. Go to original source... Go to PubMed...
    9. Cetkovská P. Primární kožní T-lymfomy: mycosis fungoides a Sézaryho syndrom. Onkologie 2010; 4(4): 233-236
    10. Cetkovská P, Pizinger K, Štork J. Kožní změny u interních onemocnění. Praha: Grada, 2010: 240 s.
    11. Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011; 29(18): 2598-2607. Go to original source... Go to PubMed...
    12. van Santen S, Roach RE, van Doorn R. Clinical Staging and Prognostic Factors in Folliculotropic Mycosis Fungoides. JAMA Dermatol. 2016; 152(9): 992-1000. Go to original source... Go to PubMed...
    13. Benner MF, Jansen PM, Vermeer MH, et al. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood. 2012; 119(7): 1643-1649. Go to original source...
    14. Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011; 118(15): 4024-4035. Go to original source...
    15. Wieser I, Oh CW, Talpur R, et al. Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients. J Am Acad Dermatol. 2016; 74(1): 59-67. Go to original source... Go to PubMed...
    16. Woo DK, Jones CR, Vanoli-Storz MN, et al. Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Arch Dermatol. 2009; 145(6): 667-74. Go to original source... Go to PubMed...
    17. Goodlad JR, Davidson MM, Hollowood K, et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland. Am J Surg Pathol. 2000; 24(9): 1279-1285. Go to original source...
    18. Senff NJ, Hoefnagel JJ, Jansen PM, et al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol. 2007; 25(12): 1581-1587. Go to original source... Go to PubMed...
    19. Ettler J, Arenberger P, Polívka J. Aktuální trendy v léčbě primárních kožních T-buněčných lymfomů. Dermatol. praxi 2018; 12(1): 31-35. Go to original source...
    20. Kaye FJ, Bunn PA Jr, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321(26): 1784-1790. Go to original source... Go to PubMed...
    21. Rubio-Gonzalez B, Zain J, Rosen ST, et al. Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions. Br J Haematol 2017; 176(1): 16-36. Go to original source... Go to PubMed...
    22. Hoppe RT, Harrison C, Tavallaee M, et al. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol 2015; 72(2): 286-292. Go to original source... Go to PubMed...
    23. Quéreux G, Brocard A, Saint-Jean M, et al. Photodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: a prospective open study and review of the literature. J Am Acad Dermatol 2013; 69(6): 890-897. Go to original source... Go to PubMed...
    24. Lewis DJ, Byekova YA, Emge DA, et al. Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series.J Dermatolog Treat. 2017; 28(6): 567-569. Go to original source... Go to PubMed...
    25. Zackheim HS. Topical carmustine (BCNU) in the treatment of mycosis fungoides. Dermatol Ther. 2003; 16(4): 299-302. Go to original source...
    26. Fialová P, Vašků V, Adam Z. Naše zkušenosti s léčbou bexarotenem u kožních T-lymfomů. Dermatol praxi 2011; 5(4): 187-191.
    27. Senff NJ, Noordijk EM, Kim YH, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008; 112(5): 1600-1609. Go to original source...
    28. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110(6): 1713-1722. Go to original source...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.